Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells

Trametinib is a MEK1/2 inhibitor and exerts anticancer activity against a variety of cancers. However, the effect of Trametinib on colorectal cancer (CRC) is not well understood. In the current study, our results demonstrate the ability of sub‐toxic doses of Trametinib to enhance TRAIL‐mediated apop...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Lin, Ding, Dapeng, Xiao, Xiaoguang, Li, Bing, Cao, Penglong, Li, Shijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299726/
https://www.ncbi.nlm.nih.gov/pubmed/32352219
http://dx.doi.org/10.1111/jcmm.15336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299726/
https://www.ncbi.nlm.nih.gov/pubmed/32352219
http://dx.doi.org/10.1111/jcmm.15336

Ejemplares similares